Simvastatin

Generic Name: Simvastatin

Brand Names: Cholib, FloLipid, Simcor, Vytorin, Zocor

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₈O_₅

CAS Number: 79902-63-9

Unique Ingredient Identifier: AGG2FN16EV

Background: Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...

Indication: Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...

Associated Conditions: Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event

Associated Therapies: -

Clinical Trials

Statin Distribution

Phase 1

Completed

Conditions: Drug Distribution

Interventions: Drug: Pravastatin
Drug: Simvastatin

First Posted Date: 2015-02-11

Last Posted Date: 2017-07-19

Lead Sponsor: Children's Mercy Hospital Kansas City

Target Recruit Count: 32

Registration Number: NCT02360826

Locations: 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States

Metformin and Simvastatin Use in Bladder Cancer

Phase 2

Conditions: Bladder Cancer

Interventions: Drug: Metformin
Drug: Simvastatin

First Posted Date: 2015-02-10

Last Posted Date: 2016-07-11

Lead Sponsor: London Health Sciences Centre

Target Recruit Count: 44

Registration Number: NCT02360618

Locations: 🇨🇦
London Health Sciences Center; Victoria Hospital, London, Ontario, Canada

Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia

Not Applicable

Completed

Conditions: Dyslipidemia

Interventions: Drug: Simvastatin
Drug: Ezetimibe
Drug: Simvastatin + Ezetimibe

First Posted Date: 2014-12-02

Last Posted Date: 2018-03-08

Lead Sponsor: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Target Recruit Count: 42

Registration Number: NCT02304926

A Study of LY2623091 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2623091
Drug: Tadalafil
Drug: Simvastatin
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2014-11-24

Last Posted Date: 2020-06-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT02300259

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis

Early Phase 1

Completed

Conditions: Solid Tumor
Cancer

Interventions: Drug: Aspirin
Drug: Simvastatin
Other: Observation

First Posted Date: 2014-11-07

Last Posted Date: 2019-05-08

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT02285738

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Acupuncture and Moxibustion for Hyperlipemia

Not Applicable

Conditions: Hyperlipidemias

Interventions: Other: acupuncture and moxibustion
Drug: Simvastatin
Other: Therapeutic Lifestyle Change

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Target Recruit Count: 210

Registration Number: NCT02269046

Locations: 🇨🇳
Changsha Hospital of Chinese Medicine, Changsha, Hunan, China
🇨🇳
Second Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China
🇨🇳
First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China

SIMOX - Induction of Oxidative Stress

Phase 2

Completed

Conditions: Oxidative Stress

Interventions: Drug: Placebo
Drug: Simvastatin

First Posted Date: 2014-10-03

Last Posted Date: 2015-03-10

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 40

Registration Number: NCT02256254

Locations: 🇩🇰
Department of Clinical Pharmacology, Copenhagen, Denmark

Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being

Phase 4

Completed

Conditions: Cardiovascular Disease
Diabetes Mellitus

Interventions: Drug: Simvastatin
Dietary Supplement: Q10

First Posted Date: 2014-10-02

Last Posted Date: 2017-01-04

Lead Sponsor: University of Copenhagen

Target Recruit Count: 35

Registration Number: NCT02255682

Locations: 🇩🇰
University of Copenhagen, Copenhagen, Denmark

Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients

Phase 2

Conditions: Uveitis

Interventions: Drug: Placebo
Drug: Simvastatin

First Posted Date: 2014-09-30

Last Posted Date: 2017-10-26

Lead Sponsor: University College, London

Target Recruit Count: 50

Registration Number: NCT02252328

Locations: 🇬🇧
Moorfields Eye Hospital, London, United Kingdom

Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Procedure: Pharmacokinetic sampling - AZD9291
Drug: Simvastatin
Drug: AZD9291 tablet dosing
Procedure: Pharmacokinetic sampling - simvastatin
Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

First Posted Date: 2014-07-22

Last Posted Date: 2024-12-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 52

Registration Number: NCT02197234

Locations: 🇪🇸
Research Site, Sevilla, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy